A federal jury in California on Thursday found that Boiron Inc. did not make false representations about Oscillococcinum even though the plaintiff had alleged it was nothing but a sugar pill.

“The vast majority of patients would tell their doctors it did help them,” said Christina Sarchio, chairwoman of the commercial class action team and a partner in the Washington office of Orrick, Herrington & Sutcliffe, who represented Boiron. “We had a lot of scientific evidence to support it.”